31 October 2023 Affini-T Therapeutics to Present Preclinical Gene Editing Data from its Program Targeting KRAS G12D at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting read more
30 October 2023 Volastra Therapeutics Announces First Patient Dosed in Phase I/II Clinical Trial of VLS-1488, One in a Portfolio of Novel and Differentiated KIF18A Inhibitors read more
24 October 2023 Scorpion Therapeutics Appoints Precision Medicine Leader Jeff Albers as Strategic Advisor read more
17 October 2023 Vigil Neuroscience Announces First Participant Dosed in Phase 1 Clinical Trial in Healthy Volunteers Evaluating VG-3927, a Small Molecule TREM2 Agonist, for Potential Treatment of Alzheimer’s Disease read more
13 October 2023 Scorpion Therapeutics Presents Preclinical Data for STX-241, a Fourth-Generation EGFR Inhibitor, at the AACR-NCI-EORTC Symposium 2023 read more